By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DiaTech Holdings, Inc. 

405 Duke Drive
Suite 240
Franklin  Tennessee  37067  U.S.A.
Phone: 615-567-0200 Fax: 615-567-0201


DiaTech Holdings is an emerging oncology focused biotechnology company specializing in cutting edge technologies utilizing molecular based clinical assays to generate actionable data for improved patient outcomes. We are currently focused on the MiCK (Micro Culture Kinetic assay), CEER (Collaborative Enzyme Enhanced Reactive-immunoassay), and flow cytometer technology platforms in support of our In Vitro Diagnostic (IVD) product development, FDA clinical validation studies and biophama collaborative projects.

Key Statistics

Ownership: Private

Web Site: DiaTech Holdings


Company News
DiaTech Oncology Receives New York State Clinical Laboratory Permit 6/25/2013 10:50:27 AM
DiaTech Oncology Test Shows Positive Results, Identifies New Therapeutic Strategies for Patients With Lung Cancer and Ovarian Cancer 6/19/2013 10:53:55 AM
DiaTech Oncology Announces Capital Raise of $18 Million 6/4/2013 10:51:06 AM
DiaTech Oncology Test Predicts Most Effective Chemotherapy for Cancer Patients 1/15/2013 9:38:05 AM
DiaTech Oncology Test Shows Improved Results for Breast Cancer Patients 12/10/2012 10:08:09 AM
DiaTech Oncology and Walter Reed Army Institute of Research Establish Pilot to Determine Best Chemotherapy for Cancer Patients 2/8/2011 7:01:35 AM
DiaTech Oncology MiCK Chemotherapy Induced Apoptosis Assay Shows Increased Response and Survival in Ovarian Cancer Patients 5/26/2010 9:37:14 AM